VIVS · VivoSim Labs, INC.
$0.32
-0.01 (-1.71%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm included in its opinion for the year ended March 31, 2026 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available.”View the 10-Q filed Aug 12, 2026
Market Cap
$4.79M
Shares
14.85M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$131K
-9%
FY2026
Net Income
-$13.84M
-456.4%
FY2026
Gross Margin
100%
+3.5pp
FY2026
Operating Margin
-8768.7%
-7.6pp
FY2026
Diluted EPS
-$5.35
-214.7%
FY2026
Operating Cash Flow
-$10.83M
-14.4%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $18K | $131K | $144K | $109K | $370K | $1.5M | $0 | $2.2M | $3.09M | $4.6M | $4.23M | $1.48M | $571K | $379K | $1.2M | |
| — | $0 | $5000 | — | — | — | $0 | $300K | $500K | $1M | $956K | $0 | $0 | $121K | $121K | |
| — | $131K | $139K | — | — | — | $0 | $1.9M | $2.59M | $3.6M | $3.27M | $1.48M | $571K | $258K | $1.08M | |
| — | 100% | 96.53% | — | — | — | — | 86.34% | 83.82% | 78.28% | 77.4% | 100% | 100% | 68.07% | 89.89% | |
| $4.32M | $4.19M | $5.03M | $5.5M | $8.89M | $3.32M | $1.1M | $5.28M | $14.75M | $17.96M | $19.55M | $18.01M | $12.92M | $7.97M | $3.44M | |
| $7.12M | $7.43M | $7.73M | $9.7M | $9.22M | $9.66M | $15.72M | $18.06M | $15.13M | $20.89M | $22.3M | $22.12M | $17.95M | $13.05M | $7.08M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1500 | |
| — | $215K | $266K | $280K | $293K | $142K | $41K | $1.14M | $980K | $1.27M | $1.15M | $815K | $472K | $387K | $195K | |
| $11.44M | $11.62M | $12.76M | $15.2M | $18.1M | $12.98M | $16.83M | $23.67M | $30.37M | $39.87M | $42.81M | $40.13M | $30.87M | — | — | |
| -$11.33M | -$11.49M | -$12.62M | -$15.09M | -$17.73M | -$11.48M | -$16.83M | -$21.48M | -$27.27M | -$35.27M | -$38.58M | -$38.64M | -$30.3M | -$20.65M | -$9.32M | |
| — | -8768.7% | -8761.11% | -13840.37% | -4792.16% | -765.27% | — | -977.91% | -882.37% | -766.26% | -911.94% | -2605.73% | -5305.95% | -5448.28% | -778.53% | |
| — | -$11.27M | -$12.35M | -$14.81M | -$17.44M | -$11.34M | -$16.79M | -$20.33M | -$26.29M | -$34M | -$37.43M | -$37.83M | -$29.83M | -$20.26M | -$9.12M | |
| $12K | $12K | $10K | — | — | — | — | — | — | — | $0 | $0 | $1000 | $13K | $1.09M | |
| $219K | $267K | $140K | $405K | $454K | $8000 | $15K | $594K | $705K | $478K | $198K | $88K | $32K | $18K | $5000 | |
| -$1M | -$2.35M | $10.13M | $417K | $474K | $33K | $2000 | $2.77M | $642K | $470K | $151K | $71K | $215K | -$5.2M | -$34.23M | |
| — | -$13.84M | -$2.49M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $5000 | $2000 | $2000 | $2000 | $2000 | $2000 | $2000 | $2000 | $3000 | $2000 | $23K | $3000 | $0 | $0 | — | |
| -$12.34M | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -$11.45M | -$16.83M | -$18.71M | -$26.64M | -$34.8M | -$38.45M | -$38.58M | -$30.08M | -$25.85M | -$43.55M | |
| — | -10567.18% | -1727.78% | -13459.63% | -4664.59% | -763.2% | — | -852% | -861.7% | -756.09% | -908.91% | -2601.15% | -5268.3% | -6820.05% | -3638.51% | |
| -$12.34M | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -$11.45M | -$16.83M | -$18.71M | -$26.64M | -$34.79M | -$38.46M | -$38.58M | -$30.08M | — | — | |
| USD/shares | — | -$5.35 | -$1.70 | -$19.25 | -$23.76 | -$15.84 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$5.35 | -$1.70 | -$19.25 | -$23.76 | -$15.84 | — | — | — | — | — | — | — | — | -$232.80 |
| shares | — | 2.59M | 1.46M | 762.08K | 726.09K | 725.3K | 575.17K | 539.82K | 480.75K | 446.85K | 407.35K | 375.24K | 331.88K | 304.75K | 179.79M |
| shares | — | 2.59M | 1.46M | 762.08K | 726.09K | 725.3K | 575.17K | 539.82K | 480.75K | 446.85K | 407.35K | 375.24K | 331.88K | 304.75K | 179.79M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2022: $1000 in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.62×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 153 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 |
|---|---|---|
| Research Development Segment | $109,000 | $370,000 |
| Mosaic Segment | $0 | $0 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Royalty | $131,000 | $119,000 | $109,000 | $370,000 |
| Product | $0 | $25,000 | — | $0 |
Key facts
CIK
1497253
CUSIP
68620A302
13F (30d)
24 filings
24 filers
Visit website
Investor relations